Answers are grounded in this paper and cite their sources.
Cuproptosis is a recently characterized form of regulated cell death with potential relevance to tumor immunity. This study developed a cuproptosis-related long non-coding RNA (Cupr-RL) signature for prognosis and computational prediction of immunotherapy response in lung adenocarcinoma (LUAD). Using The Cancer Genome Atlas (TCGA) cohort, nine prognostic Cupr-RLs were identified by least absolute shrinkage and selection operator and Cox regression analyses, and a risk-score model was constructed and internally validated. The model stratified patients into high- and low-risk groups with significantly different overall and progression-free survival. AC084871.3, a high-risk Cupr-RL, was further evaluated by reverse transcription quantitative polymerase chain reaction and fluorescence in situ hybridization. Functional enrichment, tumor mutational burden, Tumor Immune Dysfunction and Exclusion, and immune-infiltration analyses indicated distinct molecular and immune features between the two risk groups and predicted greater potential benefit from immune checkpoint blockade in the low-risk group. Weighted gene co-expression network analysis and single-cell RNA sequencing identified NLRP3 as an immune-related hub gene associated with LUAD progression. These findings support the 9-Cupr-RL signature, AC084871.3, and NLRP3 as candidate prognostic and treatment-stratification biomarkers; prospective clinical validation is required before clinical application.
No takes yet. Share an insight, caveat, or question.
sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: